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Postmenopausal, oestrogen receptor (ER)-positive 
breast cancers account for the majority of the 1·7 million 
breast cancers diagnosed annually worldwide. Adjuvant 
endocrine therapy dramatically improves survival 
among such patients, making it vital to understand the 
best treatment strategies. For decades, the Early Breast 
Cancer Trialists’ Collaborative Group meta-analyses have 
informed clinical practice in early-stage breast cancer, and 
the present report1 in The Lancet on over 30 000 women 
treated with adjuvant tamoxifen, aromatase inhibitors, 
or a sequence of those agents continues that tradition. 
The meta-analysis conﬁ rms that, in comparison with 
tamoxifen alone, aromatase inhibitor-based therapy in 
the ﬁ rst 5 years reduces the risk of recurrence (rate ratio 
0·64, 95% CI 0·52–0·78, during years 0–1; 0·80, 0·68–0·93, 
during years 2–4) and improves overall survival at 10 years 
(0·89, 0·81–0·97). Sequential therapy with tamoxifen and 
then an aromatase inhibitor during the ﬁ rst 5 years yielded 
recurrence rates that were nearly the same as those 
achieved with upfront aromatase inhibitor therapy, with 
average recurrence rates diﬀ ering by less than 1% through 
7 years of follow-up and without a survival diﬀ erence. 
Because of the enormous size of the individual trials 
that comprised the meta-analysis—most of the primary 
studies enrolled between 5000 and 10 000 women—
recurrence reductions were already well established,2–4 
and clinical guidelines recommend that postmenopausal 
women consider aromatase inhibitor-based therapy 
within the ﬁ rst 5 years of their adjuvant treatment course, 
either up front or sequentially after tamoxifen.5–7
Pooled data in the overview could facilitate subset 
analyses when low numbers of events in individual 
trials might otherwise make it hard to spot beneﬁ ts. 
The advantage of aromatase inhibitor-based treatment 
over tamoxifen alone for postmenopausal, ER-positive 
cancers extended across all commonly tested tumour 
biomarkers (ie, grade, progesterone receptor [PR] status, 
HER2 status), tumour stage (size and nodal status), and 
patient characteristics such as body-mass index and 
age. What stands out most is the absence of any single 
prognostic marker that identiﬁ es patients or tumours 
that would beneﬁ t selectively from an aromatase 
inhibitor or tamoxifen. As would be expected, higher risk 
cancers deﬁ ned by stage or HER2 status show greater 
numerical advantage for aromatase inhibitor treatment 
over tamoxifen, whereas lower risk tumours show 
smaller numerical advantage for aromatase inhibitors. 
Comparisons between drugs show that the beneﬁ ts of 
aromatase inhibitor treatment are a class eﬀ ect: there is 
nothing to distinguish one brand from another.
These new data challenge clinicians to ask two 
important questions. First, should all postmenopausal 
women with ER-positive breast cancer be oﬀ ered 
upfront aromatase inhibitor therapy as opposed to 
sequential treatment, and, if not, can clinical factors be 
identiﬁ ed that might enable clinicians to tailor therapy? 
Second, how might the longer durations of endocrine 
therapy that are now being recommended bear on the 
understanding of these data? When the trials included in 
this meta-analysis were done, the standard duration of 
adjuvant endocrine therapy was 5 years. Since then, we 
have learned that extending adjuvant treatment beyond 
5 years out to 10 years with either ongoing tamoxifen8 
or by switching to an aromatase inhibitor9 can further 
reduce breast cancer recurrences. These ﬁ ndings invite 
speculation that longer treatment duration with an 
aromatase inhibitor—longer than the 5 years studied in 
the meta-analysis—or a longer sequential programme 
would be of beneﬁ t to patients. But, at present, there 
are no data from randomised trials assessing the eﬃ  cacy 
of these approaches. Despite extensive eﬀ orts, there 
is currently no validated marker that can be used to 
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speciﬁ cally predict which patients will beneﬁ t from a 
longer duration of adjuvant endocrine treatment. The 
same prognostic markers that stratify patients for risk 
of early recurrence—stage, grade, quantitative hormone 
receptor expression, Ki67, intrinsic subtype, 21-gene 
recurrence score, and other molecular proﬁ ling assays—
are, however, also prognostic for late recurrence.10
Since the inception of adjuvant trials of aromatase 
inhibitor therapy, we have learned how to integrate 
clinical stage with many prognostic marker analyses, 
including molecular proﬁ les to risk stratify patients with 
ER-positive breast cancers. We have also altered the 
natural history of ER-positive, HER2-positive tumours—
historically and in this meta-analysis1 among the most 
aggressive of ER-positive breast cancers—with use of 
adjuvant trastuzumab. In contemporary breast cancer 
management, clinicians use these well known factors to 
assign most women with postmenopausal ER-positive 
breast cancers into lower-risk or higher-risk groups. For 
women whose tumour stage and biology put them at 
the lower end of the risk recurrence spectrum—typically 
node-negative cancers with lower grade or proliferation 
features, strong expression of ER and PR, and lack of 
HER2 expression, usually associated with luminal A 
phenotype or low recurrence score molecular proﬁ les—
the diﬀ erences in outcomes between tamoxifen-based 
and aromatase inhibitor-based therapy are lower.11
Prospective studies, not included in the meta-analysis,1 
comparing tamoxifen and aromatase inhibitor therapy 
among premenopausal women with lower-risk 
tumours, who were oﬀ ered ovarian suppression 
with an aromatase inhibitor or with tamoxifen but 
not given chemotherapy, showed small diﬀ erences 
between aromatase inhibitor-based or tamoxifen-based 
treatment.12,13 For women with tumours bearing lower 
recurrence risk, consideration of the side-eﬀ ect proﬁ le 
and preferences of the patient are critical for choosing 
the initial endocrine drug. By contrast, among women 
at greater risk of recurrence, typically those with larger or 
node-positive tumours by stage, or because of adverse 
pathological or molecular features, it is more important 
to capture the relative gains of early aromatase inhibitor 
therapy, making it preferable to start treatment with an 
aromatase inhibitor. This risk-tailored approach has been 
speciﬁ cally endorsed by expert consensus guidelines.6
Those caring for women with breast cancer realise that 
the accompanying meta-analysis1 is missing a key set of 
data: the patient experience. Women on anti-oestrogen 
treatments endure substantial side-eﬀ ects, including 
menopausal symptoms such as hot ﬂ ashes and night 
sweats. Aromatase inhibitors, in particular, are also 
associated with bone pain and arthralgias, vaginal 
dryness, sexual dysfunction, osteoporosis, bone 
fracture, and hair thinning. Some of these symptoms 
can be addressed with speciﬁ c interventions; others 
prove resistant and markedly aﬀ ect quality of life. 
Treatment-related symptoms are a primary determinant 
of patient compliance with adjuvant endocrine 
therapy.14,15 Anecdotal experience suggests that some 
patients tolerate aromatase inhibitors better than 
tamoxifen, and vice versa, and that patients intolerant of 
one aromatase inhibitor might tolerate another, especially 
after a short treatment hiatus to reset their symptom 
proﬁ le. Ultimately, the best choice for adjuvant endocrine 
therapy is a treatment the patient is willing to take. For 
most patients, especially as we envision an era of longer 
durations of endocrine therapy, it will be more important 
to assure that they are on a tolerable medication than to 
be unyielding over prescribing a speciﬁ c bottle that sits 
untouched in the medicine cabinet.
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Bisphosphonates, bone, and breast cancer recurrence
Bisphosphonates reduce bone turnover by inhibiting 
osteoclast maturation and function, and are important 
in the prevention of age-related osteoporosis and 
bone fracture,1 in the prevention of complications of 
bone metastases,2 and in the prevention of osteopenia 
and osteoporosis resulting from adjuvant aromatase 
inhibitor therapy of breast cancer.3
Over 125 years ago, in The Lancet, Paget hypothesised 
that the “soil” in which a tumour resides would be 
important for tumour propagation and growth.4 
Interruption of the interaction of tumour micrometastases 
with their microenvironmental “soil” is now a subject of 
intense investigation. Bone is an active microenvironment, 
and, in bone with high turnover, excess osteoclastic activity 
could potentially lead to excess production of growth 
factors, which could aﬀ ect survival of micrometastases.5 
Bisphosphonates, by reducing osteoclast activity, could 
in theory reduce expression of these factors, thereby 
preventing establishment of micrometastatic disease.
Clinical trials of bisphosphonates as adjuvant therapy 
for breast cancer have had mixed results. Clodronate, 
an oral ﬁ rst-generation bisphosphonate, showed a 
disease-free survival beneﬁ t versus placebo in one large 
randomised trial,6 but not in another.7 An early trial of 
zoledronic acid, a more powerful third-generation amino-
bisphosphonate, added to adjuvant aromatase inhibitor 
therapy for postmenopausal women to prevent bone loss, 
showed a non-signiﬁ cant improve ment in disease-free 
survival,3 a secondary endpoint. Larger trials comparing 
zoledronic acid to no therapy in postmenopausal 
women,8 or in premenopausal women made menopausal 
with gonadotropin-releasing hormone agonists,9 
showed signiﬁ cant disease-free survival beneﬁ ts, but 
no beneﬁ t was seen in a large randomised trial of both 
premenopausal and postmenopausal women.10
In The Lancet, the Early Breast Cancer Trialists’ 
Collaborative Group11 presents a meta-analysis of 
randomised trials of bisphosphonates as adjuvant 
systemic therapy for breast cancer. This meta-analysis 
is comprised of individual patient data derived from 
randomised adjuvant bisphosphonate trials in breast 
cancer done over the past 20 years. The analysis received 
data on 18 766 women (18 206 in randomised trials 
of 2–5 years of adjuvant bisphosphonate vs control), 
with a median follow-up of 5·6 years, 3453 ﬁ rst 
recurrences, and 2106 deaths. For all patients, there were 
borderline signiﬁ cant reductions with the addition 
of bisphosphonates at 10 years for distant recurrence 
(20·4% vs 21·8%, rate ratio [RR]=0·92, 95% CI 0·85–0·99; 
2p=0·03), bone recurrence (7·8% vs 9·0%, RR=0·83, 
0·73–0·94; 2p=0·004), breast cancer mortality (16·6% 
vs 18·4%, RR=0·91, 0·83–0·99; 2p=0·04), and all-cause 
mortality (20·8% vs 22·3%, RR=0·92, 0·85–1·00; 2p=0·06). 
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